Ananda Developments PLC Patent Applications Filed (6399Z)
May 17 2023 - 2:00AM
UK Regulatory
TIDMANA
RNS Number : 6399Z
Ananda Developments PLC
17 May 2023
17 May 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Patent Applications Filed
Ananda Developments plc (AQSE: ANA), a company whose ambition is
to be a leading provider of cannabinoid-based medicines for the
treatment of chronic, complex inflammatory pain conditions, is
pleased to announce that its wholly owned subsidiary MRX Medical
Limited, has filed four patent applications with the UK
government's Intellectual Property Office.
The applications cover three cannabinoid formulations known as
MRX1, MRX2 and its most recently invented formulation MRX3. These
formulations are being developed as cannabidiol-based medicines for
the treatment of a number of complex inflammatory indications which
are unmet by existing treatments. The fourth application covers a
proprietary method for formulating these products.
The MRX1 formulation is to be used as the Active Pharmaceutical
Ingredient (API) in two upcoming Phase II Randomised Control Trials
(RCTs) to be conducted by the University of Edinburgh. One trial is
investigating the effect of cannabidiol on chemotherapy induced
peripheral neuropathy (CIPN) and the other is investigating the
effect of cannabidiol on endometriosis.
Ananda's CEO, Melissa Sturgess, commented: "The filing of these
patent applications is an important step as we build Ananda. The
patent applications will protect the Company's intellectual
property and help to build value for shareholders."
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
ir@anandadevelopments.com
Chief Executive Officer
Melissa Sturgess
Executive Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE
LLP +44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a
leading provider of cannabinoid-based medicines for the treatment
of complex, chronic inflammatory pain conditions.
For more information, please visit:
https://anandadevelopments.com/
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXDQLFFXELXBBQ
(END) Dow Jones Newswires
May 17, 2023 02:00 ET (06:00 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From May 2024 to Jun 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Jun 2023 to Jun 2024